Skip to main content
Clinical Trials/CTRI/2014/08/004842
CTRI/2014/08/004842CompletedPhase 4

Evaluation of systemic and vascular inflammation by [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in patients with moderate to severe psoriasis randomized to different drug regimens

PGIMER0 sites16 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
PGIMER
Enrollment
16

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • Patients on topical or active light therapy

Exclusion Criteria

  • Patients with chronic inflammatory disease like diabetes mellitus, uncontrolled hypertension with SBP 180 mmHg and DBP 95 mmHg, cardiovascular disease and with coagulopathy
  • 2.Patients on any systemic therapy for psoriasis like methotrexate, retinoids or biologics in preceding 6 weeks
  • 3.Patients on tobacco, alcohol use that is 2 drinks per day or intravenous drug use.
  • 4.Participated in a research study in preceding 6 weeks
  • 5.Major surgery within 3 months of imaging
  • 6.Pregnant females
  • 7.Lactating mothers
  • 8.Patient with liver disease
  • 9.Blood glucose level 150 mg/dl
  • 10.Any other inflammatory condition in the body that in the opinion of investigator may jeopardise the validity of the study or put the patients at the greater risk

Investigators

Sponsor
PGIMER

Similar Trials